Clinical efficacy of tirilazad mesylate for treatment of endotoxemia in neonatal calves.
The clinical efficacy of the lazaroid, tirilazad mesylate, a new therapeutic agent for prophylaxis and treatment of endotoxemia, was evaluated in 24 neonatal Holstein calves. Endotoxemia was induced by IV infusion of commercial Escherichia coli lipopolysaccharide (3.25 micrograms/kg of body weight) over 3 hours. Group-1 calves were given endotoxin alone; group-2 calves were given an infusion of 0.9% sterile saline solution, then were treated with tirilazad mesylate (1.5 mg/kg) 1 hour after the infusion was started. Group-3 calves were treated with tirilazad mesylate 1 hour after the start of the endotoxin infusion, and group-4 calves were given tirilazad mesylate 1 hour before the start of the endotoxin infusion. Clinical signs of endotoxemia were mitigated by tirilazad mesylate. In addition, tirilazad mesylate protected calves from endotoxin-induced hyperglycemia; treatment after endotoxin infusion decreased the severity of hypoglycemia and prevented lactic acidosis. Treatment with tirilazad mesylate after initiation of endotoxin infusion was as protective as was pretreatment.
Rose
M L
ML
Department of Surgical Science, School of Veterinary Medicine, University of Wisconsin, Madison 53706.
Semrad
S D
SD
D000818:Animals; D000831:Animals, Newborn / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D001831:Body Temperature; D002417:Cattle; D002418:Cattle Diseases / Q000097:blood / Q000188:drug therapy*; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D005260:Female; D006339:Heart Rate; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D011281:Pregnatrienes / Q000627:therapeutic use*; D012119:Respiration; D014115:Toxemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*
D001786:Blood Glucose; D004731:Endotoxins; D007773:Lactates; D011281:Pregnatrienes; D019344:Lactic Acid; C053355:tirilazad